Health Professional Radio - Podcast
New Study Guardant360® liquid biopsy test - PIK3CA Mutations
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:08:06
- Mas informaciones
Informações:
Sinopsis
Dr. Becky Nagy, Vice President of Medical Affairs at Guardant Health discusses the phase l/ll study led by Memorial Sloan Kettering Cancer Center and published in "Nature Cancer" that showed Guardant360® liquid biopsy test identifies predictors of response to PIK3CA inhibitors in women with HR+ Metastatic Breast Cancer.
